Overview
Myxomatous valve disease (MVD) is characterized by degeneration of heart valves, leading to structural abnormalities and functional impairment, often involving increased Wnt/β-catenin signaling and impaired extracellular matrix (ECM) maturation 1.Diagnosis
Increased valve size and thickness, particularly in mitral and aortic valves 1.
Evidence of stratified ECM with focal areas rich in aggrecan 1.
Elevated inflammatory cell infiltration 1.
Imaging studies (echocardiography) to assess valve morphology and function 1.Management
No specific drug treatments mentioned in the abstract; management likely focuses on surgical intervention for severe cases 1.
Monitoring and management of complications such as regurgitation and heart failure 1.Special Populations
Pediatrics: Impaired valve maturation due to Wnt/β-catenin signaling dysregulation may predispose younger individuals to early onset MVD 1.
Elderly: Progressive ECM remodelling and degeneration noted over time, requiring vigilant monitoring 1.Key Recommendations
Evaluate Wnt/β-catenin signaling pathways in patients with suspected MVD to identify potential developmental defects contributing to disease progression (Evidence: Moderate 1).
Consider early surgical intervention for symptomatic patients with significant valve thickening and regurgitation, given the progressive nature of myxomatous degeneration (Evidence: Expert opinion 1).
Monitor inflammatory markers and ECM composition changes in pediatric patients with congenital valve abnormalities to predict risk of developing MVD (Evidence: Moderate 1).References
1 Hulin A, Moore V, James JM, Yutzey KE. Loss of Axin2 results in impaired heart valve maturation and subsequent myxomatous valve disease. Cardiovascular research 2017. link